{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-060676","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2021-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.006387+00:00","generated_at":"2026-06-27T23:52:26.852061+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TherapeuticsMD appoints Hugh O'Dowd as CEO; founder Finizio becomes Vice Chair","bullets":["Hugh O'Dowd, formerly President, appointed CEO on Dec 14, 2021 and director on Dec 18.","Robert G. Finizio steps down as CEO but remains Vice Chair of the Board.","Finizio's separation is termination without 'Cause'; he receives contractual separation benefits.","O'Dowd's existing employment agreement (filed Aug 9, 2021) continues unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-060676","json":"https://secwatch.observer/filing/0001564590-21-060676.json","markdown":"https://secwatch.observer/filing/0001564590-21-060676.md","text":"https://secwatch.observer/filing/0001564590-21-060676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/txmd-8k_20211214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:52:26.852061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"396dce1650","claim":"Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"On December 14, 2021, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Hugh O’Dowd, the Company’s President, as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"76489a2788","claim":"Robert G. Finizio was terminated as Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"Mr. Finizio’s separation as the Company’s Chief Executive Officer is a termination without “Cause,” as defined in that certain employment agreement","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c2c389d7ea","claim":"Hugh O'Dowd was appointed as director at TherapeuticsMD, Inc..","evidence_excerpt":"on December 18, 2021, the Board appointed Mr. O'Dowd as a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}